Carisma Therapeutics Inc. Quarterly Debt-to-equity in % from Q2 2020 to Q4 2023

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Carisma Therapeutics Inc. quarterly Debt-to-equity history and growth rate from Q2 2020 to Q4 2023.
  • Carisma Therapeutics Inc. Debt-to-equity for the quarter ending December 31, 2023 was 115 %, a 62.9% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q4 2023 115 +44.5 +62.9% Dec 31, 2023
Q3 2023 723 +694 +2374% Sep 30, 2023
Q2 2023 173 +137 +386% Jun 30, 2023
Q1 2023 104 +33.9 +48.4% Mar 31, 2023
Q4 2022 70.7 -60.2 -46% Dec 31, 2022
Q3 2022 29.2 -244 -89.3% Sep 30, 2022
Q2 2022 35.6 -1.87K -98.1% Jun 30, 2022
Q1 2022 70 +2.88K Mar 31, 2022
Q4 2021 131 +4.63K Dec 31, 2021
Q3 2021 274 +1.94K Sep 30, 2021
Q2 2021 1.91K +7.24K Jun 30, 2021
Q1 2021 -2.81K Mar 31, 2021
Q4 2020 -4.5K Dec 31, 2020
Q3 2020 -1.66K Sep 30, 2020
Q2 2020 -5.33K Jun 30, 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.